SCHEMBL8095249

SCHEMBL8095249

c1ccc(C(NCCNC(c2ccccc2)c2ccccc2)c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 1.00
RAB9A P51151 1/20 1.00
GRM7 Q14831 1/20 1.00
CYP3A4 P08684 3/20 0.95
ALOX15 P16050 2/20 0.95
TSHR P16473 1/20 0.95
ALDH1A1 P00352 4/20 0.57
LMNA P02545 2/20 0.57
HSD17B10 Q99714 1/20 0.57
POLB P06746 2/20 0.55
MAPT P10636 1/20 0.55
ATM Q13315 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
CHRM2 P08172 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CHRM1 P11229 1/20 0.45
SMPD1 P17405 1/20 0.45
DRD1 P21728 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3012657 0.97 CYP3A4 (1.00) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL10411095 0.90 MTOR (0.81) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL11094399 0.87 MTOR (0.75) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL8352681 0.85 MTOR (0.74) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL1118824 0.85 MTOR (0.74) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL27881139 0.85 MTOR (0.74) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL7469490 0.85 MTOR (0.74) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL11100772 0.85 MTOR (0.74) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL2586127 0.85 RAB9A (0.74) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL28729974 0.85 MTOR (0.72) MTORRAB9AGRM7CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4448776-A Method of using certain substituted aliphatic secondary amines or their salts for easing breathing BUCHER KARL (CH) 1984-05-15 US claimed
US-20230126310-A1 COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION FRAUNHOFER GES FORSCHUNG (DE) 2023-04-27 US disclosed
US-20230025575-A1 PROCESS FOR PREPARING AMINES OVER A COPPER CATALYST BASF SE (DE) 2023-01-26 US disclosed
EP-4069418-A1 PROCESS FOR PREPARING AMINES OVER A COPPER CATALYST BASF SE (DE) 2022-10-12 EP disclosed
US-20220244263-A1 METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-08-04 US disclosed
CN-114746179-A Method for producing amines on copper catalysts 巴斯夫欧洲公司 2022-07-12 CN disclosed
EP-3039126-B1 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) 2019-10-09 EP disclosed
US-20160250260-A1 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-01 US disclosed
EP-3039126-A2 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) 2016-07-06 EP disclosed
WO-2015041809-A2 SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) 2015-03-26 WO disclosed
US-20100197800-A1 Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 UNIVERSITY OF ANTWERP (BE) 2010-08-05 US disclosed
US-20100197800-A1 Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 UNIVERSITY OF ANTWERP (BE) 2010-08-05 US disclosed
WO-2008131439-A1 TREATMENT AND/OR PREVENTION OF PRESBYCUSIS BY MODULATION OF METABOTROPIC GLUTAMATE RECEPTOR 7 HOUSE EAR INSTITUTE (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025575-A1 PROCESS FOR PREPARING AMINES OVER A COPPER CATALYST AOC2, SOD1, AOC3 MTOR 3035/4885RAB9A 3433/4885GRM7 3728/4885
US-20100197800-A1 Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 GRM7, GRM3, GRM5 MTOR 2034/4885RAB9A 2982/4885GRM7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.